DT120

Product

Last mentioned: 4d ago

Timeline

  1. Anticipated Readout

    Expected top-line data from the Phase III DT120 trial.

  2. Jefferies Analyst Note

    Jefferies issues high-conviction 65-75% probability for best-in-class efficacy.

  3. Phase III Initiation

    Global Phase III trial for DT120 begins enrollment.

  4. Phase II Success

    Definium publishes robust Phase II data for DT120.

Stories mentioning DT120 1

Clinical Trials Bullish

Jefferies Bullish on Definium's DT120: 75% Odds for Best-in-Class Efficacy

Jefferies analysts have issued a high-conviction outlook on Definium Therapeutics' lead candidate, DT120, assigning a 65-75% probability that the drug will demonstrate best-in-class efficacy in its ongoing Phase III trials. This projection positions the company as a potential disruptor in its therapeutic category, significantly raising market expectations ahead of upcoming data readouts.

2 sources